Massachusetts experienced a rise in venture capital funding for the biopharmaceutical industry, totaling $7.89 billion in 2024, an increase of $220 million from 2023. Central Massachusetts firms secured $249 million, with Framingham leading at $136 million. This marks the first annual funding increase since the COVID-19 pandemic. The state accounted for 28.3% of national biopharma investments, second only to California’s 41.6%. Despite a decline from the 2021 peak of $13.66 billion, the funding surpassed pre-pandemic levels. MassBio’s CEO noted a return to investment fundamentals, highlighting strong support for biotech recovery and promising startups.